60/100BNovo-Nordisk A company profile
- CEO
- Maziar Mike Doustdar
- Employees
- 68,794
- Headquarters
- Novo Alle 1, Bagsvaerd, CR 2880, DK
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO date
- 30 Apr 1981
- Stock exchange
- NYSE
- ISIN
- US6701002056
Website:novonordisk.com
About the company
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Employees
Novo-Nordisk A/S had about 69,500 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 7.3% fewer than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Novo-Nordisk A
Institutions such as funds, banks and insurers held 7.4% of Novo-Nordisk A/S's shares on 30 June 2026, 1,456 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Novo-Nordisk A
Source: Financial Modeling PrepVerified against SEC filings